Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Pirfenidone (Primary)
- Indications Interstitial lung diseases
- Focus Therapeutic Use
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 17 Aug 2016 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.